Personalized Medicine (PM) Market Analysis By Product (PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) And Segment Forecasts To 2022

1. Follow Us:
Personalized Medicine (PM) Market Analysis, Size, Growth,
Share & Forecast to 2022 | Grand View Research Inc.
Global Personalized Medicine Market is expected to reach USD 2,452.5 billion by 2022; according to a new
study by Grand View Research, Inc. Growing number of approved companion diagnostics and biomarkers
have aided the development of advanced personalized diagnostic tests and enhanced the level of treatment
monitoring for a range of complex diseases. A significant number of diagnostics and therapeutic products,
which are currently under clinical development and investigational research, are associated with one or the
other proteomic or genomic markers and fall under category of companion diagnostics.
Personalized medicine finds extensive and indispensable applications in the field of oncology. Furthermore, a
marked technological advancement of next generation sequencing is expected to significantly enhance market
usage rates owing to, a considerable decrease in the costs of whole genome sequencing and is expected to
improve the demand for personalized medical diagnostic and therapeutic products over the forecast period.
Personalized medical care and nutrition accounted for the largest share of the market in 2014 owing to, the
presence of a significantly large consumer base, relatively less number of regulatory mandates, and the over-
the-counter nature of retail nutrition products. This large share is also due to, the highly capital-intensive nature
of implementation of healthcare information technology and telemedicine applications.
Further key findings from the study suggest:
• Personalized nutrition and wellness was the largest product segment of the market in 2014. Growing
population considerably high market usage and high accessibility are amongst key factors accounting
for its large share. Moreover, the core segments of this market viz., personalized medicine diagnostics
and therapeutics are expected to grow at the fastest rate over the forecast period due to, ongoing
technological advancements in genetic medicine.
“Global personalized medicine market is expected to reach USD 2,452.5 billion by 2022”

2. Follow Us:
• North America was the largest regional market in 2014, with revenue estimated at over USD 500.0
billion. Presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining
to cancer research, and the presence of high patient and practitioner awareness levels are some key
drivers of this market.
• Asia Pacific is expected to witness lucrative growth of over 13.0% over the forecast period. The
presence of a large population base, high market penetration of segments such as complementary and
alternative medicine, growing collaborative initiatives between western and eastern market participants
are some key factors expected to drive regional market growth over the forecast period.
• Key players of this market include GE Healthcare, Illumina Inc., Quest Diagnostics, Abbott Diagnostics,
Affymetrix, and Bayer Healthcare. Large presence of biotechnology and pharmaceutical manufacturers
is expected to keep the industry rivalry at high levels throughout the forecast period. Moreover, the
presence of extensive R&D to capitalize on novel growth opportunities is expected to further intensify
competition over the forecast period.
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/personalized-
medicine-market
Grand View Research has segmented the global personalized medicine market on the basis of product and
region:
Global Personalized Medicine Product Outlook (Revenue, USD Billion, 2012 - 2022)
• PM Diagnostics
o Genetic Testing
o Direct-to-consumer Diagnostics
o Esoteric Lab Services
o Esoteric Lab Tests
• PM Therapeutics
o Pharmaceutical
o Genomic Medicine
o Medical Devices
• Personalized Medical Care
o Telemedicine
o Healthcare Information Technology
o Diseases Management

3. Follow Us:
• Personalized Nutrition & Wellness
o Retail Nutrition
o Complementary Medicine
o Alternative Medicine
Personalized Medicine Regional Outlook (Revenue, USD Billion, 2012 - 2022)
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
• Asia Pacific
o China
o Japan
• Latin America
o Brazil
• MEA
o South Africa
Table of Content
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
2.1 Personalized medicine - Industry Snapshot & Key Buying Criteria, 2012 - 2022
Chapter 3 Personalized Medicine Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects

4. Follow Us:
3.3 Personalized medicine: Market dynamics
3.3.1 Market driver analysis
3.3.1.1 Advancement of next generation sequencing
3.3.1.2 Growing number of companion/associated diagnostics
3.3.1.3 Increasing number of retail clinics across the developed regions of North America and
Europe
3.3.1.4 Increasing prevalence of cancer
3.3.1.5 Growing healthcare expenditure triggering development of effective PM diagnostic &
therapeutic procedure for cancer
3.3.1.6 Increasing usage of biomarkers for PM cancer therapy
3.3.2 Market restraint analysis
3.3.2.1 Presence of non value-based PM diagnostics reimbursement policy
3.3.2.2 Burden of proof is greater for clinical validation for PM therapeutics
3.3.2.3 Lack of proper intellectual property regulations for personalized medical technologies
3.3.2.4 Non-structural development of biomarkers
3.4 Key Opportunities Prioritized
3.4.1 Key Opportunities Prioritized - PM Diagnostics & PM Therapeutics
3.4.2 Key Opportunities Prioritized - PM Medical Care & PM Nutrition
3.5 Industry analysis - Porter’s
3.6 Personalized medicine - PESTEL Analysis
3.7 Personalized Medicine - Application Growth Prospects Analysis
3.7.1 Personalized medicine - application opportunity v/s implementation
3.7.2 Personalized Medicine- Application Opportunities Prioritized
Chapter 4 Personalized Medicine Product Outlook
4.1 Global personalized medicine revenue share, by product, 2014 & 2022
4.2 PM diagnostics
4.2.1 PM diagnostics market, 2012 - 2022 (USD Billion)
4.2.2 Genetic testing
4.2.2.1 Genetic testing market, 2012 - 2022 (USD Billion)
4.2.3 Direct-to-consumer (DTC) diagnostics
4.2.3.1 DTC diagnostics market, 2012 - 2022 (USD Billion)
4.2.4 Esoteric lab services
4.2.4.1 Esoteric lab services market, 2012 - 2022 (USD Billion)
4.2.5 Esoteric lab tests

5. Follow Us:
4.2.5.1 Esoteric lab tests market, 2012 - 2022 (USD Billion)
4.3 PM therapeutics
4.3.1 PM therapeutics market, 2012 - 2022 (USD Billion)
4.3.2 Pharmaceuticals
4.3.2.1 Pharmaceuticals market, 2012 - 2022 (USD Billion)
4.3.3 Genomic medicine
4.3.3.1 Genomic medicine market, 2012 - 2022 (USD Billion)
4.3.4 Medical devices
4.3.4.1 Medical devices market, 2012 - 2022 (USD Billion)
4.4 Personalized medical care
4.4.1 Personalized medical care market, 2012 - 2022 (USD Billion)
4.4.2 Telemedicine
4.4.2.1 Telemedicine market, 2012 - 2022 (USD Billion)
4.4.3 Health information technology
4.4.3.1 Health information technology market, 2012 - 2022 (USD Billion)
4.4.4 Disease Management
4.4.4.1 Disease management market, 2012 - 2022 (USD Billion)
4.5 Personalized nutrition & wellness
4.5.1 Personalized nutrition & wellness market, 2012 - 2022 (USD Billion)
4.5.2 Retail nutrition
4.5.2.1 Retail nutrition market, 2012 - 2022 (USD Billion)
4.5.3 Complementary medicine
4.5.3.1 Complementary medicine market, 2012 - 2022 (USD Billion)
4.5.4 Alternative medicine
4.5.4.1 Alternative medicine market, 2012 - 2022 (USD Billion)
Chapter 5 Personalized Medicine Regional Outlook
5.1 Global personalized medicine revenue share, by region, 2014 & 2022
5.2 North America
5.2.1 North America personalized medicine market, 2012 - 2022 (USD Billion)
5.2.2 U.S.
5.2.2.1 U.S. market, 2012 - 2022 (USD Billion)
5.2.3 Canada
5.2.3.1 Canada market, 2012 - 2022 (USD Billion)
5.3 Europe

6. Follow Us:
5.3.1 Europe personalized medicine market, 2012 - 2022 (USD Billion)
5.3.2 Germany
5.3.2.1 Germany market, 2012 - 2022 (USD Billion)
5.3.3 UK
5.3.3.1 UK market, 2012 - 2022 (USD Billion)
5.4 Asia Pacific
5.4.1 Asia Pacific personalized medicine market, 2012 - 2022 (USD Billion)
5.4.2 Japan
5.4.2.1 Japan market, 2012 - 2022 (USD Billion)
5.4.3 China
5.4.3.1 China market, 2012 - 2022 (USD Billion)
5.5 Latin America
5.5.1 Latin America personalized medicine market, 2012 - 2022 (USD Billion)
5.5.2 Brazil
5.5.2.1 Brazil market, 2012 - 2022 (USD Billion)
5.6 MEA
5.6.1 MEA personalized medicine market, 2012 - 2022 (USD Billion)
5.6.2 South Africa
5.6.2.1 South Africa market, 2012 - 2022 (USD Billion)
Chapter 6 Competitive Landscape
6.1 GE Healthcare
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Illumina Incorporated
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Asuragen Incorporated
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking

7. Follow Us:
6.3.4 Strategic Initiatives
6.4 Cepheid
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Dako A/S
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 Exact Science Corporation
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 Biogen
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 Decode Genetics Inc.
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 Exagen Diagnostics Inc.
6.10.1 Company Overview
6.10.2 Financial Performance

8. Follow Us:
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 Genelex Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 Precision Biologics Incorporated
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Qiagen Incorporated
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Celera Diagnostics
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Affymetrix Incorporated
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 DNA Direct Inc.
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 Agendia N.V.
6.17.1 Company Overview

9. Follow Us:
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based research across a range of
industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com